‹ Home
Exported

CSTE COVID-19 Response Resource Repository

This repository is intended for jurisdictions to easily share resources related to the COVID-19 outbreak response. Please refer to the CDC website for the most up-to-date official guidance for public health departments. _______________________________________________________________________________________________________________________ The audience for this Basecamp is CSTE members working at STLT health departments participating in COVID-19 response activities. Appropriate resources to upload include health department-created guidance documents, resources, or other useful tools that may be helpful to other jurisdictions during their response. Forums may be used to pose questions for discussion among STLT jurisdictions. ______________________________________________________________________________________________________________________ Prior to using this Basecamp, please ensure you review the **INSTRUCTIONS FOR BASECAMP USAGE** folder, which contains "Basecamp Repository Instructions and Rules" and "How to Change Basecamp Notification Settings." Before posting in the Forums, please review the first posting “How to Use Forums” for rules and instructions. _______________________________________________________________________________________________________________________ IMPORTANT: This Basecamp is not housed behind the CSTE firewall and users are not monitored by the CSTE National Office, therefore CSTE does not recommend uploading any sensitive resources. _______________________________________________________________________________________________________________________ Note: This Basecamp is not monitored by CSTE National Office staff on a daily basis. If you need to REPORT a Basecamp user, forum posting, or uploaded resource, please contact the National Office at preparedness@cste.org or call 770-458-3811 during normal business hours.
Beverly Christner, Senior Director of Operations at CSTEStephen Clay, Webmaster at CSTEAmanda Masters, Director of Workforce Development at CSTEMonica Schroeder, Program Analyst at CSTETom HauptDhara Shah, Director of Epidemiology Programs at CSTEVivian HawkinsErin MurrayBrooke Beaulieu, Surveillance/Informatics Program Analyst at CSTEMaria Patselikos, Evaluation Analyst at CSTELisa McHugh, Assistant Bureau Director, Bureau of Epidemiology Lynn SosaMarion Kainer, TNShundra Clinton, Member Services Coordinator at CSTEBecky Lampkins, Manager, Surveillance/Informatics Program at CSTE +265 others
STLT Shared Resources Publications Related to COVID-19 Treatment
Last modified
Document NEJMe2020388.pdf
Document NEJMoa2016638.pdf
Document jmcp_ft95_6_8.pdf
Document jama_patel_2020_ed_200051.pdf
Document lancethydro.pdf
Document nejmoa2007764.pdf
Document 1-s2.0-S0002937820301976-main.pdf
Document Early short course corticosteroids in hospitalized patients with COVID-19.pdf
Document Use of prone positioning in nonintubated patients with COVID-19 and hypoxemic acute respiratory failure.pdf
Document Respiratory parameters in patients with COVID-19 after using noninvasive ventilation in the prone position outside the ICU.pdf
Document Should clinicians use chloroquine or hydroxychloroquine alone or in combination with azithromycin for the prophylaxis or treatment of COVID-19.pdf
Document How to discover antiviral drugs quickly.pdf
Document The Antiviral Compound Remdesivir Potently Inhibits RNA-Dependent RNA Polymerase from MERS.pdf
Document ciaa576.pdf
Document jama_ison_2020_vp_200109.pdf
Document A detailed guide to the coronavirus drugs and vaccines in development.docx
Document Potential Role of Extracorporeal Membrane Oxygenation in Preparing for Most Critically Ill COVID-19 Patients.pdf
Document The Antiviral Compound Remdesivir Potently Inhibits RNA-Dependent RNA Polymerase from MERS.pdf
Document Drug Treatment Options for COVID-19.pdf
Document Diagnosis, Treatment and Prevention of COVID-19 Infections in Children.pdf
Document Care for Critically I’ll Patients with COVID-19.pdf
Document COVID-19 Treatment- A Review of Early and Emerging Options.pdf
Document Chloroquine Phosphate Has Shown Apparent Efficacy in Treatment of COVID-19 Associated Pneumonia in Clinical Studies.pdf
Document COVID-19_The Search for Effective Therapy .pdf
Document A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe COVID-19.pdf
Document Surviving Sepsis Campaign- Guidelines on the Management of Critically Ill Adults with COVID-19.pdf
Document Toward universal deployable guidelines for the care of patients with Covid-19.pdf
Document Treating Covid-19.pdf
Document Hydroxychloroquine and azithromycin as a treatment of Covid-19 .pdf
Document Efficacy of hydroxychloroquine in patients with Covid-19 .pdf
Document COVID-19 infection and renin angiotensin system blockers.pdf
Document EUA_hdroxychloroquine phosphate.pdf
Document FDA_EUA_use of chloroquin phosphate.pdf
Document The COVID-19 Pandemic in the U.S..pdf
Document IDSA guidelines on treatment and management of patients with COVID-19.pdf
Document Pharmacologic treatments for COVID-19 .pdf
Document Compassionate use of remdesivir for patients with severe COVID-19.pdf
Document Use of Hydroxychloroquine and Chloroqu ine During the COVID-19 Pandemic.docx
Document Effect of convalescent plasma therapy on viral shedding and survival in COVID-19 patients.pdf
Document Mild or moderate COVID-19.pdf
Document Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for COVID-19.pdf
Document EUA FDA Authorization Letter_01May2020 (002).pdf
Document GS-EUAFactSheet5-1-20.pdf
Document jama_bollyky_2020_vp_200082.pdf
Document nejmc2008043.pdf
Document nejmoa2012410 (1).pdf